


NCTN Genitourinary Cancer Trials Portfolio (Open as of 3/15/2025)


Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



NCTN Genitourinary Cancer Trials Portfolio (Open as of 3/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:



NCTN Genitourinary Cancer Trials (Open as of 3/15/2025)

Protocol Number	Phase	Protocol Title
A031701	II	A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A031702	II	Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
A031801	II	A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)
A031803	II	Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
A032102	II	PREcision Dagnostics in Prostate Cancer Treatment (PREDICT)
A032103	III	MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
A032201	III	Short Term Intensified Pembrolizumab (KEYtruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE
CCTG-PR24	III	Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Brachytherapy Boost in Patients with Unfavorable Risk Localized Prostate Cancer (ASCENDE-SBRT)
CCTG-PR26	III	A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
EA8134	III	InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
EA8191	III	Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE)
EA8192	II/III	A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
EA8211	III	Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
EA8212	III	A Randomized Phase III Trial of Intravesical BCG Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naive High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
NRG-GU008	III	Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*)
NRG-GU009	III	Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
NRG-GU010	III	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU011	II	A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
NRG-GU012	II	Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
NRG-GU013	III	The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
NRG-GU014	II	Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)
S1802	III	Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
S1931	III	Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
S1937	III	A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
S2012	II/III	Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
S2200	II	A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
S2210	II	A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations
S2312	III	A Phase III Study of Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-A3	II	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
EAY191-E5	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
EAY191-N5	II	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
EAY191-S3	II	Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>